HGH Fragment 176-191 vs Semaglutide
A side-by-side research comparison of HGH Fragment 176-191 and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | HGH Fragment 176-191 | Semaglutide |
|---|---|---|
| Full name | Human Growth Hormone Fragment 176-191 | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound | FDA Approved |
| Mechanism | Mimics lipolytic action of HGH by stimulating beta-3 adrenergic receptors on adipocytes, increasing cyclic AMP and hormone-sensitive lipase activity. Does not affect IGF-1. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | 1,817 Da | 4,114 Da |
| Half-life | 3-4 hours | 7 days (168 hours) |
| Bioavailability | High (SubQ) | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | 250-500 mcg | 0.25 mg → titrate up to 2.4 mg |
| Frequency | 1-2x daily | Once weekly |
| Route | Subcutaneous | Subcutaneous injection |
HGH Fragment 176-191 reported benefits
- Targeted fat loss
- No IGF-1 elevation
- No glucose impairment
- No bone/organ growth effects
- Improved body composition
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.